Short answer
ImmunityBio, Inc. (IBRX) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). ImmunityBio reported Q2 and six-month results ended June 30, 2026.
ImmunityBio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- ImmunityBio reported Q2 and six-month results ended June 30, 2026
- Financial position as of June 30, 2026 covered in the announcement
- Full operating metrics and business updates available in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 net product revenue $50.7M, up 92% YoY and 15% sequentially, marking eight consecutive quarters of growth
- First-half net product revenue $94.8M, up 121%, supporting accelerating ANKTIVA commercialization
- GAAP net loss $230.4M versus $92.6M, driven largely by non-cash liability fair-value losses
- Adjusted net loss improved to $81.0M from $89.9M, indicating better underlying operating performance
- Cash, cash equivalents, and marketable securities $357.4M; regulatory catalysts include January 6, 2027 FDA action date
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ImmunityBio, Inc. 8-K filings
Get the next IBRX 8-K as it lands
Follow IBRX for push alerts, or ask the research agent what this filing means.